Compare ARK Genomic Revolution ETF (ARKG) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance

ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.

Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.

HLAL trades at $72.95, showing minimal daily movement with a slight decline of 0.03%. Technical indicators signal a bullish trend based on moving averages, though oscillators are neutral. The stock lacks recent fundamental data, with key ratios like P/E and P/S unavailable. A small dividend of $0.02 is scheduled for June 2026, but no recent earnings or cash flow updates are present.

The outlook is mixed due to incomplete financials; technical strength suggests potential upside, but fundamental opacity poses risks. Investors face uncertainty without current revenue or profit metrics, requiring caution until updated SEC filings or analyst reports emerge to assess valuation and growth prospects accurately.